Solvonis Therapeutics PLC (LSE:SVNS) CEO Anthony Tennyson talked with Proactive's Stephen Gunnion about the company’s SVN-SDN-14 programme, which is targeting trauma-related mental health disorders such as post-traumatic stress disorder (PTSD). Tennyson explained that PTSD affects an estimated 13 million people in the United States and around 20 million across the US, UK and main EU economies, yet there are currently no licensed medicines for the condition. He said the company’s approach is to develop a new class of medicines that modulate serotonin, dopamine and noradrenaline receptors to trigger “pro-social responses” and help patients recover more effectively and rapidly. According to Tennyson, existing treatments such as SSRIs and talk therapy often fail to deliver effective results. The CEO outlined Solvonis’s dual R&D strategy — repurposing approved medicines in its lead programmes SVN-001 and SVN-002 to reduce costs and timelines, while also pursuing novel compounds for mental health disorders and addictions. Positive preclinical results from SVN-SDN-14 have identified three high-performing candidates, now moving into in vivo studies. Tennyson said this provides “optionality and depth” to select the lead candidate with the highest probability of success and commercial potential. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and enable notifications for future content. #SolvonisTherapeutics #PTSDTreatment #MentalHealthInnovation #DrugDevelopment #BiotechNews #SVNSDN14 #ClinicalResearch #InvestorUpdates #ProactiveInvestors #PharmaPipeline